JP2012525387A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012525387A5 JP2012525387A5 JP2012508503A JP2012508503A JP2012525387A5 JP 2012525387 A5 JP2012525387 A5 JP 2012525387A5 JP 2012508503 A JP2012508503 A JP 2012508503A JP 2012508503 A JP2012508503 A JP 2012508503A JP 2012525387 A5 JP2012525387 A5 JP 2012525387A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- aqueous pharmaceutical
- composition according
- aqueous
- polyethylene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 15
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 15
- 229960002707 bendamustine Drugs 0.000 claims description 12
- YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 claims description 12
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 5
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 5
- -1 GELUCIRE 44/14 Chemical compound 0.000 claims description 4
- 208000034578 Multiple myelomas Diseases 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 239000006186 oral dosage form Substances 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 238000000034 method Methods 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 41
- 239000002202 Polyethylene glycol Substances 0.000 claims 28
- 229920001223 polyethylene glycol Polymers 0.000 claims 28
- ARIWANIATODDMH-UHFFFAOYSA-N rac-1-monolauroylglycerol Chemical compound CCCCCCCCCCCC(=O)OCC(O)CO ARIWANIATODDMH-UHFFFAOYSA-N 0.000 claims 20
- 229920001451 polypropylene glycol Polymers 0.000 claims 15
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 claims 9
- 229940068939 glyceryl monolaurate Drugs 0.000 claims 8
- GHBFNMLVSPCDGN-UHFFFAOYSA-N rac-1-monooctanoylglycerol Chemical compound CCCCCCCC(=O)OCC(O)CO GHBFNMLVSPCDGN-UHFFFAOYSA-N 0.000 claims 6
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 claims 5
- 229940087068 glyceryl caprylate Drugs 0.000 claims 5
- 229920001993 poloxamer 188 Polymers 0.000 claims 5
- 229940044519 poloxamer 188 Drugs 0.000 claims 5
- 229920000136 polysorbate Polymers 0.000 claims 5
- 229950008882 polysorbate Drugs 0.000 claims 5
- 239000000725 suspension Substances 0.000 claims 4
- ZVUNTIMPQCQCAQ-UHFFFAOYSA-N 2-dodecanoyloxyethyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCOC(=O)CCCCCCCCCCC ZVUNTIMPQCQCAQ-UHFFFAOYSA-N 0.000 claims 3
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 3
- 208000026310 Breast neoplasm Diseases 0.000 claims 3
- 208000017604 Hodgkin disease Diseases 0.000 claims 3
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 3
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 3
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims 3
- 239000000499 gel Substances 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 229960001295 tocopherol Drugs 0.000 claims 3
- 229930003799 tocopherol Natural products 0.000 claims 3
- 235000010384 tocopherol Nutrition 0.000 claims 3
- 239000011732 tocopherol Substances 0.000 claims 3
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims 3
- FPVVYTCTZKCSOJ-UHFFFAOYSA-N Ethylene glycol distearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCOC(=O)CCCCCCCCCCCCCCCCC FPVVYTCTZKCSOJ-UHFFFAOYSA-N 0.000 claims 2
- SHBUUTHKGIVMJT-UHFFFAOYSA-N Hydroxystearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OO SHBUUTHKGIVMJT-UHFFFAOYSA-N 0.000 claims 2
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 claims 2
- 239000002285 corn oil Substances 0.000 claims 2
- 235000005687 corn oil Nutrition 0.000 claims 2
- 239000006184 cosolvent Substances 0.000 claims 2
- 239000004064 cosurfactant Substances 0.000 claims 2
- 239000006185 dispersion Substances 0.000 claims 2
- 229940100608 glycol distearate Drugs 0.000 claims 2
- 239000007788 liquid Substances 0.000 claims 2
- 239000002609 medium Substances 0.000 claims 2
- RUOJZAUFBMNUDX-UHFFFAOYSA-N propylene carbonate Chemical group CC1COC(=O)O1 RUOJZAUFBMNUDX-UHFFFAOYSA-N 0.000 claims 2
- 229940032159 propylene carbonate Drugs 0.000 claims 2
- 229960004063 propylene glycol Drugs 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 2
- 239000007962 solid dispersion Substances 0.000 claims 2
- 239000006104 solid solution Substances 0.000 claims 2
- 239000000243 solution Substances 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- 239000004094 surface-active agent Substances 0.000 claims 2
- 239000003826 tablet Substances 0.000 claims 2
- 150000003626 triacylglycerols Chemical class 0.000 claims 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 2
- JVKUCNQGESRUCL-UHFFFAOYSA-N 2-Hydroxyethyl 12-hydroxyoctadecanoate Chemical compound CCCCCCC(O)CCCCCCCCCCC(=O)OCCO JVKUCNQGESRUCL-UHFFFAOYSA-N 0.000 claims 1
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 229920002534 Polyethylene Glycol 1450 Polymers 0.000 claims 1
- 229920001304 Solutol HS 15 Polymers 0.000 claims 1
- AOBORMOPSGHCAX-UHFFFAOYSA-N Tocophersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-UHFFFAOYSA-N 0.000 claims 1
- 238000013270 controlled release Methods 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 229940074046 glyceryl laurate Drugs 0.000 claims 1
- 229940100242 glycol stearate Drugs 0.000 claims 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000004530 micro-emulsion Substances 0.000 claims 1
- 229940113116 polyethylene glycol 1000 Drugs 0.000 claims 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 1
- 229940068968 polysorbate 80 Drugs 0.000 claims 1
- 229920000053 polysorbate 80 Polymers 0.000 claims 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims 1
- 239000007939 sustained release tablet Substances 0.000 claims 1
- ZHSKUOZOLHMKEA-UHFFFAOYSA-N 4-[5-[bis(2-chloroethyl)amino]-1-methylbenzimidazol-2-yl]butanoic acid;hydron;chloride Chemical compound Cl.ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 ZHSKUOZOLHMKEA-UHFFFAOYSA-N 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 230000000269 nucleophilic effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 208000008342 Leukemia P388 Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 1
- 229960001467 bortezomib Drugs 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 229960003433 thalidomide Drugs 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17342309P | 2009-04-28 | 2009-04-28 | |
| US61/173,423 | 2009-04-28 | ||
| PCT/US2010/029578 WO2010126676A1 (en) | 2009-04-28 | 2010-04-01 | Oral formulations of bendamustine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012525387A JP2012525387A (ja) | 2012-10-22 |
| JP2012525387A5 true JP2012525387A5 (https=) | 2013-05-16 |
Family
ID=42174186
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012508503A Pending JP2012525387A (ja) | 2009-04-28 | 2010-04-01 | ベンダムスチンの経口製剤 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20120157505A1 (https=) |
| EP (1) | EP2424506A1 (https=) |
| JP (1) | JP2012525387A (https=) |
| CN (1) | CN102413816A (https=) |
| CA (1) | CA2760085A1 (https=) |
| MX (1) | MX2011011109A (https=) |
| WO (1) | WO2010126676A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR072777A1 (es) | 2008-03-26 | 2010-09-22 | Cephalon Inc | Formas solidas de clorhidrato de bendamustina |
| PL3158991T3 (pl) | 2010-01-28 | 2021-09-27 | Eagle Pharmaceuticals, Inc. | Preparaty bendamustyny |
| JO3659B1 (ar) | 2010-06-02 | 2020-08-27 | Astellas Deutschland Gmbh | أشكال جرعات بينداموستين عن طريق الفم وإستخداماته العلاجية |
| US20130202693A1 (en) * | 2010-06-02 | 2013-08-08 | Astellas Deutschland Gmbh | Oral Dosage Forms of Bendamustine |
| CN102125693A (zh) * | 2011-01-25 | 2011-07-20 | 福建科瑞药业有限公司 | 一种盐酸噻加宾药物组合物及其制备方法 |
| EP2814487A4 (en) * | 2012-02-14 | 2015-07-15 | Eagle Pharmaceuticals Inc | FORMULAS FROM BENDAMUSTIN |
| CA2867295C (en) * | 2012-03-20 | 2020-08-11 | Eagle Pharmaceuticals, Inc. | Formulations of bendamustine |
| PL2827863T3 (pl) | 2012-03-20 | 2019-07-31 | Eagle Pharmaceuticals, Inc. | Ciekła kompozycja do zastosowania w sposobie leczenia stanów reagujących na bendamustynę u pacjentów wymagających obniżonych objętości do podawania |
| EP2641592A1 (en) | 2012-03-23 | 2013-09-25 | Salmon Pharma GmbH | Pharmaceutical formulation comprising bendamustine |
| ES2957541T3 (es) | 2013-08-27 | 2024-01-22 | Vasilios Voudouris | Composiciones farmacéuticas de bendamustina |
| CA2941632C (en) | 2014-03-13 | 2023-10-24 | Vasilios VOUDOURIS | Bendamustine solid dispersions and continuous infusion |
| CN105726472B (zh) * | 2016-03-25 | 2019-12-13 | 南京康玻斯医药科技有限公司 | 苯达莫司汀药剂组合物及应用 |
| SG11202003098WA (en) | 2017-10-05 | 2020-05-28 | Tube Pharmaceuticals Gmbh | Oral bendamustine formulations |
| CN110123747A (zh) * | 2019-04-26 | 2019-08-16 | 嘉兴市爵拓科技有限公司 | 苯达莫司汀的制剂 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE159289C (https=) * | 1903-10-08 | 1905-03-16 | ||
| DD159289A1 (de) * | 1981-06-01 | 1983-03-02 | Uwe Olthoff | Verfahren zur herstellung stabiler injektionsloesungen von n-lostverbindungen |
| DE10306724A1 (de) | 2002-02-28 | 2003-09-18 | G O T Therapeutics Gmbh | Vesikuläre Verkapselung von Bendamustin |
| JP2008519047A (ja) * | 2004-11-05 | 2008-06-05 | セフアロン・インコーポレーテツド | 癌処置 |
| US8436190B2 (en) * | 2005-01-14 | 2013-05-07 | Cephalon, Inc. | Bendamustine pharmaceutical compositions |
| CN101219113A (zh) * | 2008-01-28 | 2008-07-16 | 济南帅华医药科技有限公司 | 含苯达莫司汀的复方抗癌缓释注射剂 |
-
2010
- 2010-04-01 MX MX2011011109A patent/MX2011011109A/es unknown
- 2010-04-01 WO PCT/US2010/029578 patent/WO2010126676A1/en not_active Ceased
- 2010-04-01 CA CA2760085A patent/CA2760085A1/en not_active Abandoned
- 2010-04-01 EP EP10712267A patent/EP2424506A1/en not_active Withdrawn
- 2010-04-01 CN CN2010800183962A patent/CN102413816A/zh active Pending
- 2010-04-01 JP JP2012508503A patent/JP2012525387A/ja active Pending
-
2011
- 2011-10-28 US US13/284,220 patent/US20120157505A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012525387A5 (https=) | ||
| TWI876477B (zh) | 用於治療hiv之蛋白殼抑制劑 | |
| ES2739194T3 (es) | Formulación y método para aumentar la biodisponibilidad oral de fármacos | |
| US8703726B2 (en) | Methods for treating prostate conditions | |
| US12527807B2 (en) | Drug composition containing abiraterone acetate, and preparation method therefor and application thereof | |
| JP5670335B2 (ja) | ベンダムスチン液体製剤 | |
| JP7280192B2 (ja) | プリナブリン組成物及びその使用 | |
| JP4718653B2 (ja) | シクロスポリンの投与のための親水性二成分系 | |
| CN104736144B (zh) | 外排抑制剂组合物和使用此组合物治疗的方法 | |
| JP6182510B2 (ja) | カバジタキセルの新規の抗腫瘍的使用 | |
| WO2024189607A1 (en) | Methods and bioavailable highly permeable compounds for diseases treatment | |
| US20120202801A1 (en) | Methods for treating breast cancer | |
| WO2019084462A1 (en) | FORMULATION OF A COMPOUND MODULATING KINASES | |
| KR20190039936A (ko) | 다양한 소양증성 병태를 치료하기 위한 뉴로키닌-1 길항제의 용도 | |
| TWI522357B (zh) | 用於治療癌症及其他疾病或病症之醫藥組合物 | |
| Pensel et al. | Enhanced chemoprophylactic and clinical efficacy of albendazole formulated as solid dispersions in experimental cystic echinococcosis | |
| PT1615640E (pt) | Combinações antineoplásticas | |
| JP2018512403A (ja) | 置換２，３−ジヒドロイミダゾ［１，２−ｃ］キナゾリン類の使用 | |
| CA3126239A1 (en) | Method for treating osteoarthritis pain by administering resiniferatoxin | |
| RU2017144574A (ru) | Пероральная композиция целекоксиба для лечения боли | |
| CN113853374A (zh) | 具有增强的生物利用度的化合物形式及其制剂 | |
| KR20120008069A (ko) | 카바지탁셀 및 카페시타빈을 포함하는 항종양 조합물 | |
| WO2019222231A1 (en) | Compositions comprising bisfluoroalkyl-l,4-benzodiazepinone compounds for treating adenoid cystic carcinoma | |
| ES3042094T3 (en) | Vaginal delivery systems containing selective estrogen receptor modulator (serm) and uses thereof | |
| WO2021154976A1 (en) | Methods of treating brain cancer with panobinostat |